Stay updated on Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.

Latest updates to the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded the MeSH term Malignant lymphoma, large B-cell, diffuse. Introduced a Resources section with a link to the Genetic and Rare Diseases Information Center.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedAdded revision v3.5.0 and removed revision v3.4.3.SummaryDifference0.0%

- Check33 days agoChange DetectedAdded new revision entry v3.4.3 with March 2026 dates; removed prior revision entry v3.4.2 and February 2026 dates.SummaryDifference0.3%

- Check40 days agoChange DetectedAdded Results Posted with primary and secondary outcomes (ORR, CRR, PFS, OS) and related dates, including Results First Submitted/Posted timestamps. Also attached the Study Protocol and Statistical Analysis Plan PDF.SummaryDifference1%

- Check61 days agoChange DetectedAdded: Results Submitted and Revision: v3.4.2; Removed: No Results Posted and Revision: v3.4.1. The page now shows that results have been submitted and reflects the latest site revision.SummaryDifference0.4%

- Check68 days agoChange DetectedThe page shows a site-wide notice about a funding lapse affecting information currency and a page revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Rituximab/Pembrolizumab +/- Lenalidomide in Lymphoma Clinical Trial page.